सामग्री पर जाएँ

दवाओं की अंतःक्रिया

Aprepitant + Lomitapide

गंभीरता: निषिद्ध

Aprepitant and Lomitapide: contraindicated interaction.

अंतिम अपडेट

केवल स्वास्थ्य पेशेवरों के लिए — मात्र संदर्भ हेतु। यह पृष्ठ संक्षिप्त सारांश है, चिकित्सकीय सलाह नहीं है और आधिकारिक लेबल या नैदानिक निर्णय का विकल्प नहीं है। दवा लिखने या देने से पहले हमेशा जाँच करें।

इस पृष्ठ की नैदानिक सामग्री केवल अंग्रेज़ी में उपलब्ध है।

सारांश

Lomitapide is a sensitive CYP3A4 substrate and moderate CYP3A4 inhibitors such as aprepitant can substantially raise its levels. This increases the risk of hepatotoxicity and gastrointestinal adverse effects.

इस इंटरैक्शन का सरल भाषा में अर्थ

Aprepitant and Lomitapide are not normally used together. Taking them at the same time is expected to cause harm or make one of them unsafe, so a different medicine is usually chosen for one of the two.

Aprepitant belongs to Gastrointestinal Tract; Lomitapide belongs to Cardiovascular.

साक्ष्य स्तर: Moderate

ऐसा क्यों होता है

Inhibition of CYP3A4-mediated lomitapide metabolism by aprepitant.

क्या करें

Avoid per lomitapide labeling, which contraindicates moderate and strong CYP3A4 inhibitors; use an antiemetic without CYP3A4 inhibition, such as ondansetron.

फार्मासिस्ट से क्या पूछें

  • Is there an alternative to one of these two medicines for me?
  • If both are essential, who is monitoring me and how often?
  • Which symptoms mean I should stop and seek help straight away?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ सदस्यों के लिए

पूरा पेज खोलें

Aprepitant और Lomitapide की पूरी प्रबंधन सलाह, अतिरिक्त नोट्स, साक्ष्य का विवरण और पूरे पर्चे का इंटरैक्शन चेकर खोलने के लिए खाता बनाएँ और Pro+ ट्रायल शुरू करें।

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

वेब पर Pro+ को 14 दिन मुफ़्त आज़माएँ। कार्ड की ज़रूरत नहीं।

अक्सर पूछे जाने वाले प्रश्न

Can I take Aprepitant with Lomitapide?

MediHelp rates the interaction as contraindicated. Aprepitant and Lomitapide are not normally used together. Taking them at the same time is expected to cause harm or make one of them unsafe, so a different medicine is usually chosen for one of the two. Lomitapide is a sensitive CYP3A4 substrate and moderate CYP3A4 inhibitors such as aprepitant can substantially raise its levels. This increases the risk of hepatotoxicity and gastrointestinal adverse effects.

How serious is the interaction between Aprepitant and Lomitapide?

MediHelp rates it contraindicated, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid per lomitapide labeling, which contraindicates moderate and strong CYP3A4 inhibitors; use an antiemetic without CYP3A4 inhibition, such as ondansetron.

What other medicines interact with Aprepitant?

MediHelp also lists interactions of Aprepitant with, for example, Pimozide, Avapritinib, Bosutinib. The full list is on the Aprepitant page.

MediHelp ऐप में पूर्ण मोनोग्राफ़, खुराक और इंटरैक्शन चेकर

MediHelp ऐप में पूरा संदर्भ खोलें, कई दवाओं की अंतःक्रियाएँ जाँचें और खुराक टूल इस्तेमाल करें।

A–Z ब्राउज़ करें · दवाओं की अंतःक्रिया

ऐप पाएँ साइन इन